Edoxaban versus Warfarin in Patients with Non-valvular Atrial Fibrillation in the US FDA Approval Population: An analysis from the ENGAGE AF-TIMI 48 trial
Conclusion In the FDA approved cohort of the ENGAGE AF-TIMI 48 trial, treatment with edoxaban 60/30 mg was superior to warfarin in the prevention of SSE and significantly reduced cardiovascular death and bleeding, especially fatal bleeding and hemorrhagic stroke.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Coumadin | Heart | Hemorrhagic Stroke | Ischemic Stroke | Stroke | Warfarin